KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortization of Deferred Charges (2018 - 2022)

TherapeuticsMD's Amortization of Deferred Charges history spans 8 years, with the latest figure at $2.6 million for Q3 2022.

  • For Q3 2022, Amortization of Deferred Charges rose 74.81% year-over-year to $2.6 million; the TTM value through Sep 2022 reached $21.1 million, up 317.92%, while the annual FY2021 figure was $5.7 million, 124.68% up from the prior year.
  • Amortization of Deferred Charges reached $2.6 million in Q3 2022 per TXMD's latest filing, down from $7.9 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $9.0 million in Q1 2022 to a low of $119753.0 in Q3 2018.
  • Average Amortization of Deferred Charges over 5 years is $1.7 million, with a median of $887000.0 recorded in 2020.
  • Peak YoY movement for Amortization of Deferred Charges: surged 54.98% in 2021, then skyrocketed 611.32% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $119950.0 in 2018, then skyrocketed by 127.74% to $273171.0 in 2019, then surged by 224.71% to $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then skyrocketed by 68.65% to $2.6 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Amortization of Deferred Charges are $2.6 million (Q3 2022), $7.9 million (Q2 2022), and $9.0 million (Q1 2022).